SPRAVATO® for Major Depression with Acute Suicidal Ideation in Baltimore — The FDA-Approved Indication Explained
SPRAVATO® is FDA-approved for depressive symptoms in adults with MDD and acute suicidal ideation or behavior. Baltimore Ketamine Clinic explains the indication and what to expect.
How Baltimore Ketamine Clinic’s Dual-Expertise Model Changes Mental Health Care
Baltimore Ketamine Clinic combines anesthesiology and psychiatric nursing expertise. Learn how Ivana Mitic’s dual training benefits ketamine and SPRAVATO® patients.
SPRAVATO® for Treatment-Resistant Depression in Baltimore: What to Know
Baltimore Ketamine Clinic offers SPRAVATO® for treatment-resistant depression. Ivana Mitic, CRNA, PMHNP explains who qualifies and how treatment works.
Treatment-Resistant Anxiety in Baltimore: When SSRIs Aren’t Enough
Baltimore Ketamine Clinic treats treatment-resistant anxiety with IV ketamine and SPRAVATO®. Ivana Mitic, CRNA, PMHNP explains options when SSRIs fall short.
SPRAVATO® for Treatment-Resistant Depression: FDA-Approved Ketamine Therapy
SPRAVATO® is FDA-approved for treatment-resistant depression. Learn about this nasal spray ketamine therapy at Baltimore Ketamine Clinic.
The Clinical Benefits of SPRAVATO®: Rapid-Acting Depression Relief
For individuals struggling with treatment-resistant depression (TRD) or major depressive disorder with suicidal ideation, finding effective relief can often feel like an uphill battle. Fortunately, innovative treatments like SPRAVATO® are changing the landscape of depression care. This nasal esketamine treatment offers a new avenue for those who have not found success with traditional antidepressants. In […]
What Does a Spravato Treatment Session Look Like?
Spravato is a breakthrough treatment for individuals suffering from treatment-resistant depression. It is a nasal spray that contains esketamine, a derivative of ketamine. This article aims to provide a comprehensive understanding of what a Spravato treatment session entails and what patients can expect during the process.
What Is The Success Rate Of Spravato Treatment?
Spravato, also known as esketamine, is an innovative treatment that has gained attention for its use in treating treatment-resistant depression. Since its approval by the FDA in 2019, there has been much interest in understanding its success rate and effectiveness.
Who Can Administer Spravato?
Spravato is a medication that is used for the treatment of depression, specifically in adults who have not found relief from other antidepressant medications. Due to its specialized nature and potential risks, it is essential that Spravato is administered by qualified healthcare professionals.